SEER is an authoritative source of information on cancer incidence and survival in the United States. SEER currently collects and publishes cancer incidence and survival data from population-based cancer registries covering approximately 28 percent of the U.S. population.
CML, BCR-ABL1 status unknown, Accelerated phase (AP)
CML, BCR-ABL1 status unknown, Blastic phase (BP)
CML, BCR-ABL1 status unknown, Chronic phase (BP)
No delineation of translocation, BCR-ABL1, or Phil chromosome noted to qualify for ICD-O-3 9863.
Specific term as defined by WHO, codes as 9875/3 and indicates the process has Ph+, BCR-ABL1 fusion and/or t(9;22)(q34;q11) demonstrated, as defined by ICD-O-3 for 9875 as well. Presumably myelogenousleukemia without genetic studies done would be coded to 9863.
Chronic myeloidleukemia, NOS is a generic disease description. DCO cases or path report only cases may stay in this classification. In most cases, NOS histology is only the provisional diagnosis; the physician will run further diagnostic procedures and look for various clinical presentations to identify a more specific disease. Further review of the medical record should be done to look for the tests listed as definitive diagnosis. The more specific chronic myeloidleukemias are: Chronic myelogenousleukemia, BCR-ABL1 positive; Atypical chronic myeloidleukemia, BCR-ABL1 negative; Chronic myelomonocytic leukemia; and Juvenile myelomonocytic leukemia. If the characteristics of a specific subtype of chronic myeloidleukemia develop later in the course of the disease, change the histology code to the more specific diagnosis.